Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial

Maria Ekholm, Pär Ola Bendahl, Mårten Fernö, Bo Nordenskjöld, Olle Stål, Lisa Rydén

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

20 Citeringar (SciVal)

20 Citeringar
1 Doktorsavhandling (sammanläggning)

1 resultat

2018

Prognostic and Predictive Markers in Primary Breast Cancer - Quality Assurance and Long-term Effects of Adjuvant tamoxifen Treatment
Ekholm, M., 2018, Lund: Lund University: Faculty of Medicine. 138 s.
Forskningsoutput: Avhandling › Doktorsavhandling (sammanläggning)

Öppen tillgång
Fil

995 Nedladdningar (Pure)